Institute for Clinical and Economic Review (ICER)
Sarah Emond serves as the President and CEO of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization focused on enhancing evidence application in the healthcare system to ensure fair pricing and access. Emond has held various leadership roles within ICER, including President-Elect and Executive Vice President and Chief Operating Officer. Prior to ICER, Emond co-directed the Boston Chapter of The New Leaders Council and served as Principal at SKE Communications, providing strategic consultancy in health care communications and public policy. Additional experience includes internships and managerial roles in health policy and corporate communications at organizations such as Blue Cross Blue Shield of Massachusetts Foundation, Oscient Pharmaceuticals, and Feinstein Kean Healthcare. Educational credentials include a Master of Public Policy from The Heller School for Social Policy and Management at Brandeis University and an AB in Biological Sciences from Smith College.
This person is not in any teams
Institute for Clinical and Economic Review (ICER)
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.